UroGen Pharma Ltd.

Contributing Author

Recent Articles by UroGen Pharma Ltd.

Oct-27	Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI Effective January 1, 2026 URGN GlobeNewswire
Oct-02	ZUSDURI Clinical Review Published in Reviews in Urology Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer URGN GlobeNewswire
Sep-08	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) URGN GlobeNewswire
Aug-21	UroGen Pharma to Present at Upcoming Investor Conferences URGN GlobeNewswire
Aug-07	UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI and Reports Second Quarter 2025 Financial Results URGN GlobeNewswire
Aug-05	UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer URGN GlobeNewswire
Jul-29	UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025 URGN GlobeNewswire
Jul-28	UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology URGN GlobeNewswire
Jul-21	UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer URGN GlobeNewswire
Jul-07	UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer URGN GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.